Important Safety Information Full Prescribing Information


Nausea & Vomiting
ALOXI Eases Nausea and Vomiting and Helps Patients Stay Strong After Chemo

The most commonly known types of CINV include acute and delayed.1

Acute CINV occurs within the first 24 hours following chemotherapy administration.1

Delayed CINV occurs more than 24 hours after chemotherapy is administered.2

Clinicians should be aware of risk factors for CINV, especially in patients receiving combination therapies:3

  • History and severity of CINV
  • History of morning sickness
  • History of motion sickness
  • Low alcohol use
  • Female sex
  • Less than 50 years of age

Indication

In adults, ALOXI® (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

Important Safety Information

  • Aloxi is contraindicated in patients known to have hypersensitivity to the drug of any of its components
  • Most commonly reported adverse reactions in chemotherapy-induced nausea and vomiting include headache (9%) and constipation (5%)

For more information about ALOXI, please see Full Prescribing Information

References
  1. National Cancer Institute. Overview. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional/page2. Accessed July 7, 2010.
  2. Roila F., et al. Daily challenges in oncology practice. What do we need to know about antiemetics? Annals of Oncology. 2006;17(Supplement 10):x90-x94.
  3. National Cancer Institute. General risk factors and etiologies. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional/page4. Accessed July 7, 2010.